Risankizumab: Daily Practice Experience of High Need Patients
Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody wh...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/6/1769 |
| _version_ | 1797595951100067840 |
|---|---|
| author | Alexandra M. G. Brunasso Martina Burlando Fabrizio Amoruso Luisa Arancio Giovanna Malara Raffaella Manzo Maria Antonia Montesu Giacomo Caldarola |
| author_facet | Alexandra M. G. Brunasso Martina Burlando Fabrizio Amoruso Luisa Arancio Giovanna Malara Raffaella Manzo Maria Antonia Montesu Giacomo Caldarola |
| author_sort | Alexandra M. G. Brunasso |
| collection | DOAJ |
| description | Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns. |
| first_indexed | 2024-03-11T02:43:34Z |
| format | Article |
| id | doaj.art-41fee14c34d9423eb907cb05d6f80626 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T02:43:34Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-41fee14c34d9423eb907cb05d6f806262023-11-18T09:27:55ZengMDPI AGBiomedicines2227-90592023-06-01116176910.3390/biomedicines11061769Risankizumab: Daily Practice Experience of High Need PatientsAlexandra M. G. Brunasso0Martina Burlando1Fabrizio Amoruso2Luisa Arancio3Giovanna Malara4Raffaella Manzo5Maria Antonia Montesu6Giacomo Caldarola7Department of Internal Medicine, Villa Scassi Hospital ASL3, 16100 Genoa, ItalyDepartment of Dermatology, Dipartimento di Scienze Della Salute, DISSAL, University of Genoa, 16100 Genoa, ItalyDermatology Unit, Azienda Ospedaliera di Cosenza, 87100 Cosenza, ItalyUnit of Dermatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20019 Milan, ItalyUnità Operativa Complessa di Dermatologia, Azienda Ospedaliero-Universitaria, 89121 Reggio Calabria, ItalyU.O.C. Dermatologia, ASL Salerno Ospedale Tortora Pagani, 84121 Salerno, ItalyDepartment of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli—IRCCS, 00118 Rome, ItalyPsoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns.https://www.mdpi.com/2227-9059/11/6/1769psoriasisrisankizumabmonoclonal antibody |
| spellingShingle | Alexandra M. G. Brunasso Martina Burlando Fabrizio Amoruso Luisa Arancio Giovanna Malara Raffaella Manzo Maria Antonia Montesu Giacomo Caldarola Risankizumab: Daily Practice Experience of High Need Patients Biomedicines psoriasis risankizumab monoclonal antibody |
| title | Risankizumab: Daily Practice Experience of High Need Patients |
| title_full | Risankizumab: Daily Practice Experience of High Need Patients |
| title_fullStr | Risankizumab: Daily Practice Experience of High Need Patients |
| title_full_unstemmed | Risankizumab: Daily Practice Experience of High Need Patients |
| title_short | Risankizumab: Daily Practice Experience of High Need Patients |
| title_sort | risankizumab daily practice experience of high need patients |
| topic | psoriasis risankizumab monoclonal antibody |
| url | https://www.mdpi.com/2227-9059/11/6/1769 |
| work_keys_str_mv | AT alexandramgbrunasso risankizumabdailypracticeexperienceofhighneedpatients AT martinaburlando risankizumabdailypracticeexperienceofhighneedpatients AT fabrizioamoruso risankizumabdailypracticeexperienceofhighneedpatients AT luisaarancio risankizumabdailypracticeexperienceofhighneedpatients AT giovannamalara risankizumabdailypracticeexperienceofhighneedpatients AT raffaellamanzo risankizumabdailypracticeexperienceofhighneedpatients AT mariaantoniamontesu risankizumabdailypracticeexperienceofhighneedpatients AT giacomocaldarola risankizumabdailypracticeexperienceofhighneedpatients |